Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib and Rituximab in Untreated Mantle Cell Lymphoma
NCT05214183Phase 2Active, not recruiting
- Sponsor
- Nordic Lymphoma Group
- Start
- Dec 2021
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of acalabrutinib in mantle cell lymphoma (MCL), sponsored by Nordic Lymphoma Group. Started Dec 2021; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05214183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214183.